RESEARCH ARTICLE

Gastric bypass prevents diabetes in genetically modified mice and chemically induced diabetic mice

Chenyu Zhu1, Rui Xu1, Yuxin Li2, Michael Andrade2, Deng Ping Yin2*

1 The First College of Clinical Medical Science, CTGU, and Yichang Central People’s Hospital, Yichang, Hubei, China, 2 The Department of Surgery at University of Chicago, Chicago, Illinois United States of America

☯ These authors contributed equally to this work.
* dyin@surgery.bsd.uchicago.edu

Abstract

Obese subjects have increase probabilities of developing type 2 diabetes (T2D). In this study, we sought to determine whether gastric bypass prevents the progression of prediabetes to overt diabetes in genetically modified mice and chemically induced diabetic mice. Roux-en-Y gastric bypass (RYGB) was performed in C57BL/KsJ-db/db null (BKS-db/db) mice, high-fat diet (HFD)-fed NONcNZO10/LtJ (NZO) mice, C57BL/6 db/db null (B6-db/db) mice and streptozotocin (STZ)-induced diabetic mice. Food consumption, body weight, fat mass, fast blood glucose level, circulating insulin and adiponectin and glucose tolerance test were analyzed. The liver and pancreatic tissues were subjected to H&E and immunohistochemistry staining and islet cells to flow cytometry for apoptotic analysis. RYGB resulted in sustained normoglycemia and improved glucose tolerance in young prediabetic BKS-db/db mice (at the age of 6 weeks with hyperglycemia and normal insulinemia). However, RYGB neither reversed hyperglycemia in adult diabetic BKS-db/db mice (12 weeks old) nor attenuated hyperglycemia in STZ-induced diabetic mice. These results demonstrate that gastric bypass improves hyperglycemia in genetically modified prediabetic mice; however, it should be performed prior to β-cells exhaustion.

Introduction

Obesity is associated with insulin resistance and type 2 diabetes (T2D) and is considered a public health crisis, responsible for an exponential increase in healthcare costs [1]. In response to insulin resistance, pancreatic β-cells compensate by increasing insulin secretion characterized by hyperglycemia and hyperinsulinemia or normal insulinemia [2]. This metabolic setting can be maintained for long periods of time [3–6]. Eventually, in some individuals who are genetically predisposed to develop T2D, pancreatic β-cells are unable to maintain the increased
demand for insulin, and overt diabetes ensues [7–9]. To prevent or delay the development of overt diabetes, bariatric surgery, including gastric bypass, have been initiated. However, while gastric bypass effectively improves obesity and insulin resistance, complete resolution of diabetes occurs in only 42.3 to 59.4% of patients [10–12]. A shorter duration of diabetes prior to surgery corresponds to a higher rate of diabetes remission. Likewise, less favorable outcomes may be associated with longer duration of diabetes, poor preoperative hyperglycemia control and reduced β-cell function [13,14]. Thus, an early surgical intervention like gastric bypass in obese patients may be a viable strategy to prevent the progression of diabetes.

Frequently used animal models of obesity and diabetes are rodents that are exposed to obesogenic diets predisposing the animals to gaining excessive weight [15]. An established mouse RYGB model induces significant weight loss, reduces body fat, improves insulin sensitivity and ameliorates liver steatosis in high-fat diet (HFD)-induced obese mice [16–19]. However, HFD-induced obesity and insulin resistance reveal hyperinsulinemia, insulin resistant and hyperglycemia without β-cell failure or insulin depletion [20]. Mice with mutations of individual or several genes are susceptible to develop obesity and diabetes. In leptin receptor deficient db/db mice, C57BL/KsJ-db/db nude (BKS-db/db) mice carry a mutation in the leptin receptor gene characterized by extreme obesity and early onset of hyperglycemia and hyperinsulinemia or normal insulinemia. An uncontrolled rise in blood sugar or overt diabetes develops due to severe depletion of pancreatic β-cells with aging [21]. Young prediabetic BKS-db/db mice (< 6 weeks old) show early metabolic derangements and hyperglycemia and normal insulinemia before the onset of β-cell failure [22]; thereby, providing an opportunity to test whether gastric bypass can prevent the progression of prediabetes to overt diabetes. C57BL/6 background leptin receptor deficient (B6-db/db) homozygous mice reveal compensatory hyperplasia of β-cells and continued hyperglycemia without depletion of β-cells, which are used to model T2D from 1 to 3 phases [23,24]. This allows us to test whether gastric bypass improves obesity and hyperglycemia in prediabetic states, compared to BKS-db/db mice. T2D results from a combination of genetic and environmental factors and is increasingly attributed to environmental factors, particularly HFD. NONcNZO10/LtJ (NZO) is a recombinant congenic strain developed at the Jackson Laboratory to model human obesity induced T2D. These mice develop overt diabetes in 40% of male mice, and HFD accelerates the progression to fasting hyperglycemia in 100% of male mice [25,26]. This model provides us the opportunity to test whether gastric bypass can prevent diabetes induced by genetical and environmental factors. In the chemically induced diabetic model, pancreatic β-cells are severely damaged by administration of streptozotocin (STZ), mimicking type 1 diabetes (T1D) phenotype [27,28]. The availability of mouse insulin promoter (MIP)-driven luciferase transgenic (MIP-luc) mice provides an opportunity to visualize insulin promoter activity, which lets us determine whether gastric bypass can improve β-cell activity when β-cells are exhausted.

In this study, we ask whether gastric bypass can prevent the development of prediabetes to overt diabetes, using genetically modified prediabetic and diabetic mice and chemically induced diabetic MIP-luc mice. Our results show the efficacy of gastric bypass in preventing diabetes if it is performed prior to severe β-cell exhaustion.

**Materials and methods**

**Mice and surgery**

C57BL/KsJ-db/db nude (BKS-db/db), C57BL/6-db/db nude (B6-db/db) and NONcNZO10/LtJ (NZO) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mouse insulin promoter (MIP)-driven luciferase transgenic (MIP-luc) mice were used to analyze insulin promoter activity [29]. Mice were housed at 23°C on a 07:00–19:00 light cycle. Young BKS-db/
db mice (6 weeks old with blood glucoses of 300–350mg/dl and normal insulinemia), adult BKS-db/db mice (≥12 weeks old with blood glucoses of ≥400 mg/dl and reduced plasma insulin levels) and adult B6-db/db mice (≥12 weeks old with blood glucoses of ≤300 mg/dl) were used. All BKS-db/db and B6-db/db mice were fed chow for the duration of the experiment. NZO mice were fed with chow up to 6 weeks of age and underwent RYGB or sham surgery followed by high-fat diet (HFD, 60% fat, Bio-Serv) feeding up to the endpoint.

To test whether RYGB reverses chemically induced diabetes, MIP-luc mice were made diabetic (blood glucoses were ≥300 mg/dl for more than two consecutive days) by a single intravenous injection of STZ (170 mg/kg, Sigma-Aldrich, St. Louis, MO). The mouse models and diet feeding are described in Table 1 and the S1 File.

RYGB was performed with a success rate of ≥80% as described in our previous reports and the S1 File [16,17,30], and RYGB with a small gastric pouch was used in this study. Blood glucose was tested before and after surgery using a glucose meter (SureStep, LifeScan, Inc., Milpitas, CA). In the sham procedure, the stomach, duodenum and jejunum were mobilized, and the esophagus, stomach and jejunum were clamped without incision followed by the closure of the abdomen. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. At the endpoint (12 weeks post-surgery), mice with RYGB or sham surgery were sacrificed under the anesthesia of isoflurane, and the livers were collected for H&E staining. All surgery was performed under isoflurane, and all efforts were made to minimize suffering. The protocol (ACUP number: 72357) was approved by the University of Chicago Institutional Animal Care and Use Committee.

**Whole body composition**

Body mass was measured using the mq10 NMR analyzer (Bruker Optics Inc., Billerica, MA) following a 2-hr fast.

**Intraperitoneal glucose tolerance tests (IPGTT)**

Mice were fasted for 4 hrs prior to the IPGTT. Blood was sampled from the tail vein at 0, 30, 60, 90 and 120 min after an intraperitoneal injection of 20% dextrose dosed at 2g/kg body weight. Blood glucose was measured using a blood glucose meter (SureStep, Lifescan, Inc.).
The area under the cure (AUC) was calculated using the trapezoidal rule [31]. Any result exceeding the maximum reading of meter (showing HIGH) was recorded as 600 mg/dL.

**Plasma insulin and adiponectin analyses**

Circulating insulin and adiponectin were analyzed by the MilliPlex map kit using the Luminex 200 System analyzer (Millipore, Co., Billerica, MA) following company’s instruction.

**Flow cytometry for annexin V positive cell analysis**

Single islet cells were collected by collagenase digestion and Ficoll gradient procedure [28,32] at 4 weeks post-surgery. Cells were subjected to fluorescein-labeled annexin V (Annexin V-FITC) in concert with propidium iodide (PI) using the ApoScreen Annexin V Apoptosis Kit (SouthernBiotech, Birmingham, Alabama). Annexin V-positive cells were analyzed by flow cytometry (3-laser BD LSRII system, San Jose, CA). Cells in early apoptosis are Annexin V-FITC-positive and PI-negative, and cells in late apoptosis are both FITC Annexin V- and PI-positive.

**Bioluminescence imaging (BLI)**

BLI in MIP-luc mice allows for direct visualization of β-cell viability under isoflurane anesthesia [29]. Luciferin (Roche Diagnostics, Indianapolis, IN) was injected intravenously at a dose of 50mg/kg. Mice were housed inside a light-tight box and imaged with an ICCD camera (Hamamatsu C2400-32, Hopkinton, MA). Light emission through the ventral body was detected as photon counts over a standardized area of the organs of interest using the ARGUS-50 software for image processing [29,33].

**Statistics**

Statistical significance was analyzed by ANOVA test (StatView 4.5, Abacus Concepts, Berkeley, CA). *P*-value of < 0.05 was considered significant. Results were presented as the mean ± SEM. The level of significance was set at a probability of *p* < 0.05.

**Results**

**Gastric bypass improves hyperglycemia and glucose tolerance in young prediabetic BKS-db/db mice**

RYGB or sham surgery was performed in young prediabetic BKS-db/db mice showing hyperglycemia and normal insulinemia. Diet intake was analyzed in untreated (BKS-db/db Control), sham surgery treated (BKS-db/db-SHAM) and RYGB-treated (BKS-db/db-RYGB) mice. Fig 1a shows that Chow consumption in BKS-db/db-Control mice was 6.2 ± 0.5 g/day at 6 weeks of age and increased to 7.2 ± 0.5 g/day at 18 weeks of age. Chow intake in BKS-db/db-RYGB mice was reduced immediately post-surgery, and BKS-db/db-SHAM mice revealed the similar change to RYGB mice in the first 2 weeks post-surgery. However, diet consumption was increased 4 weeks after surgery in BKS-db/db-SHAM mice and reduced through the end point (12 weeks post-surgery) in BKS-db/db-RYGB mice. To test the effects of caloric restriction and surgical stress on the induction of weight loss and fat reduction, a separate group of mice underwent sham surgery and were pair fed (SHAM-PF). The amount of diet provided to SHAM-PF mice is matched to that consumed by the mice with RYGB. The results in Fig 1b show that RYGB decreased body weight, and SHAM-PF experienced similar weight changes in BKS-db/db mice (BKS-db/db-SHAM-PF vs. BKS-db/db-RYGB, *p* > 0.05, Fig 1b). Fat mass in BKS-db/db mice was enhanced compared to wild-type (WT) C57BL/6 LEAN mice and
significantly reduced by RYGB (BKS-db/db-RYGB vs. BKS-db/db-Control, \( p < 0.05 \) from the 1\textsuperscript{st} week to 12 weeks post-surgery, Fig 1c).

Blood glucose was increased in young BKS-db/db mice (\( \geq 300 \text{mg/dL} \)), and RYGB resulted in a persistent normoglycemia, whereas blood glucose in SHAM-PF mice had only transient declines and increased 2 weeks post-surgery (Fig 2a). SHAM-PF (\( p < 0.01 \)) improved glucose tolerance compared to control BKS-db/db mice in the first two weeks after surgery (Fig 2b),

https://doi.org/10.1371/journal.pone.0258942.g001
whereas this improvement persisted in RYGB mice \((p < 0.001)\), but not in SHAM-PF mice \((p > 0.05\) after 4 weeks of surgery). Liver steatosis developed in BKS-db/db mice and was significantly improved by RYGB procedure at 12 weeks, compared to the untreated and SHAM-PF liver (Fig 2c).
RYGB improves β-cell viability, enhances insulin secretion and inhibits β-cell apoptosis

Plasma insulin was decreased in adult diabetic BKS-db/db mice (2.3 ± 0.5 ng/ml) as compared to young prediabetic BKS-db/db (8.1 ± 0.7 ng/ml) mice (Fig 3a). SHAM-PF fails to significantly rise plasma insulin levels (3.7 ± 0.35 ng/ml), and RYGB maintained plasma insulin levels

Fig 3. RYGB maintains circulating insulin and adiponectin levels, preserves β-cell mass and prevents β-cell apoptosis when performed in young prediabetic BKS-db/db mice. a. Circulating insulin levels. Young BKS-db/db mice (6 weeks old, n = 5); Adult BKS-db/db mice (12 weeks old, n = 5); SHAM-PF, sham surgery and pair-feeding (n = 5); and RYGB, BKS-db/db mice with RYGB at 6 weeks of age (N = 8). *: RYGB vs. SHAM-PF and Adult Control, p < 0.01. b. Circulating adiponectin levels. *: Young BKS-db/db vs. Adult BKS-db/db, and RYGB vs. SHAM-PF and Adult Control, p < 0.01. c. Annexin V flow cytometry analysis of apoptotic β-cells. LEAN, C57BL/6 mice; CONTROL adult BKS-db/db mice; SHAM-PF, BKS-db/db mice with sham surgery and pair-feeding, and RYGB, BKS-db/db mice with RYGB 4 weeks after surgery (n = 4 in each group). PI, propidium iodide positive; Annex-PI, Annexin V and PI double positive islet cells. #: SHAM-PF and RYGB vs. Control, p < 0.001; and #: RYGB vs. SHAM-PF, p < 0.01.

https://doi.org/10.1371/journal.pone.0258942.g003
at 8.3 ± 0.3 ng/ml at 12 weeks post-surgery comparable to that in young prediabetic BKS-db/db mice (BKS-RYGB vs. BKS-Adult and BKS-SHAM-PF, p < 0.001, Fig 3a).

Adiponectin in the circulation, an anti-inflammatory adipokine, was reduced in adult BKS-db/db mice versus young BKS-db/db mice (7.0 ± 1.0 μg/ml vs. 13.3 ± 1.2 μg/ml, p = 0.015). RYGB maintained adiponectin at levels well-matched to young BKS-db/db mice (RYGB vs. Control and SHAM-PF, p < 0.01, Fig 3b).

To test whether RYGB improved β-cell apoptosis in BKS-db/db mice, islet cells were collected at 4 weeks post-surgery for Annexin V analysis by flow cytometry [28,32]. Increased apoptotic islet cells were found in control BKS-db/db mice (CONTROL, Fig 3d) compared to lean C57BL/6 mice (LEAN). Both SHAM-PF and RYGB reduced Annex V- and PI-double positive cells (Annex V-PI, p <0.001); however, when compared to SHAM-PF, RYGB further reduced apoptotic cells (p < 0.01, Fig 3d). The results show that RYGB improves β-cell viability and prevents β-cell apoptosis. These changes were also reflected by the observed changes in blood glucose and plasma insulin levels (Fig 3a).

**Gastric bypass improves β-cell mass and prevents diabetes in HFD-fed NZO mice**

NZO male mice were fed chow in the first 6 weeks of age followed by HFD feeding to the end point (12 weeks). HFD accelerated body weight gain compared to chow (Fig 4a). Four of eight chow-fed and all HFD-fed NZO males developed hyperglycemia (fasting blood glucose of > 300 mg/dl) after 6 weeks on HFD. SHAM-PF delayed but did not completely prevent hyperglycemia in 6 of 8 mice. RYGB prevented hyperglycemia in 100% of HFD-fed NZO mice.

---

**Fig 4. RYGB prevents diabetes in NONcNZO10/1J (NZO) male mice.** a. RYGB resulted in weight loss in high-fat diet (HFD)-fed NZO mice. NZO-Chow, NZO chow-fed mice (n = 8); NZO-HFD, NZO mice with HFD starting at 6 weeks old (n = 8); NZO-SHAM-PF, sham surgery and pair feed with HFD starting at 6 weeks old (n = 8), and NZO-RYGB, RYGB with HFD starting at 6 weeks old (n = 10). NZO-RYGB vs. NZO-HFD, p < 0.01 from 2 weeks to 12 weeks; NZO-RYGB vs. NZO-SHAM-PF, p < 0.05 from 6 weeks to 12 weeks, and NZO-SHAM-PF vs. NZO-HFD, p < 0.01 from 4 weeks to 12 weeks post-surgery. b. RYGB improved hyperglycemia in HFD-fed NZO mice. NZO-Chow, chow-fed NZO mice (n = 8); NZO-HFD, HFD-fed NZO mice (n = 8); NZO-SHAM-PF, NZO mice with sham surgery and pair feeding (n = 8), and NZO-RYGB, HFD-fed NZO mice with RYGB (n = 10). NZO-RYGB vs. NZO-HFD and NZO-SHAM-PF, p < 0.01 from 6 weeks to 12 weeks post-surgery. The shaded area represents a normal range of lean mouse blood glucose levels.

https://doi.org/10.1371/journal.pone.0258942.g004
(Fig 4b), suggesting that HFD accelerates the development of overt diabetes, which can be prevented by RYGB, and RYGB, but not SHAM-PF, preserves insulin+ cells, contributing to improved hyperglycemia in HFD-fed NZO mice.

**RYGB improves glucose tolerance in C57BL/6-db/db null mice**

C57BL/6 db/db nude mice (B6-db/db) have persistent insulin resistance without β-cell depletion [34,35]. To test whether RYGB improves insulin resistance in B6-db/db mice, RYGB was performed in adult B6-db/db mice (≥ 12 weeks old), and IPGTT was performed starting at one-week post-surgery up to 12 weeks after surgery. Fig 5a shows that RYGB maintained normoglycemia through 12 weeks post-surgery (RYGB vs. B6-db/db-CONTROL and B6-db/db-SHAM-PF, p < 0.05). Fig 5b revealed that RYGB improved glucose tolerance through 12 weeks post-surgery (B6-db/db RYGB vs. B6-db/db-Control and B6-db/db-SHAM-PF, p < 0.001).

**Gastric bypass fails to improve glucose tolerance in genetic and chemically induced diabetic mice**

To determine whether RYGB reverses diabetes when β-cells were severely damaged or exhausted, RYGB surgeries were performed in adult diabetic BKS-db/db mice (≥ 12 weeks of age) with blood glucoses of ≥ 400 mg/dl. In contrast to young prediabetic BKS-db/db mice, RYGB did not improve hyperglycemia in adult diabetic BKS-db/db mice (Fig 5c).

STZ induced diabetes (blood glucoses of ≥ 300 mg/dl) in 75–80% of MIP-luc mice after 3–7 days of injection (referred to as day 0 in Fig 5d and 5e). Fig 5d indicates that RYGB failed to reverse hyperglycemia, and diabetic mice remained hyperglycemic through 4 weeks post-surgery. Bioluminescence imaging (Fig 5e) reveals reduced luciferase activity in STZ-induced diabetic mice, indicating decrease of β-cell activity, which cannot be improved by RYGB.

**Discussion**

In prediabetes metabolic states such as obesity and glucose intolerance, β-cells biosynthesize and secrete more insulin in response to increased blood glucose level. With chronic hyperglycemia, there is a perpetually high demand for insulin, and β-cells eventually become exhausted, resulting in insufficient insulin synthesis and secretion causing overt diabetes [36]. The current study shows that RYGB preserves β-cell mass and prevents or slows the progression toward the insulin-deficient state, thereby preventing the development of overt diabetes in genetically modified prediabetic mice. However, RYGB neither reverses hyperglycemia nor improves β-cell viability in genetically modified diabetic mice and chemically induced diabetic mice. Gastric bypass must be performed before β-cells are completely exhausted, and it is ineffective in reversing the overt diabetic state once β-cells have already been severely damaged.

Although weight loss is associated with decreased insulin resistance, recent clinical results suggest that gastric bypass normalizes insulin sensitivity well before a significant reduction in body weight [37,38]. We have recently shown that RYGB induces sustained weight loss, fat mass reduction and improves insulin resistance in HFD-induced obese mice [16,17]. However, in BKS-db/db mice, body weight and fat mass are restored to pre-surgery levels from the second week post-surgery, and there is no statistical difference with SHAM-PF mice. However, while RYGB mice maintain normoglycemia post-surgery, SHAM-PF mice maintain hyperglycemia through the end point with a severe loss of β-cell mass, indicating that RYGB prevents the progression to overt diabetes and that this remarkable effect is independent of weight loss.

Consistent with a previous report that plasma insulin is decreased by 40% and 80% at 8 and 12 weeks of age, respectively [39], our findings show that plasma insulin in adult diabetic BKS-
Fig 5. RYGB improves hyperglycemia in adult B6-db/db mice, but not in adult diabetic BKS-db/db mice and chemically induced diabetic mice. a. RYGB maintained normoglycemia in adult B6-db/db mice. *: B6-db/db-RYGB (n = 8) vs. B6-db/db-Control (n = 5) and B6-db/db-SHAM-PF (n = 5), p < 0.05. b. RYGB improved glucose tolerance (intraperitoneal glucose tolerance test) in adult B6-db/db mice. *: B6-db/db-RYGB (n = 8) vs. B6-db/db-Control (n = 5) and B6-db/db-SHAM-PF (n = 5), p < 0.01. c. RYGB failed to reverse hyperglycemia in adult diabetic BKS-db/db (12 weeks old) mice. BKS-PF, adult BKS-db/db mice with pair-feeding; BKS-SHAM-PF, adult BKS-db/db mice with sham surgery and pair-feeding, and BKS-RYGB, BKS-db/db mice with RYGB (n = 4 in each group). d. RYGB failed to reverse hyperglycemia in streptozotocin (STZ)-induced diabetic MIP-luc mice. STZ-Control, untreated STZ-induced diabetic mice (n = 5); STZ-SHAM, STZ-induced diabetic mice with sham surgery (n = 5), and STZ-RYGB, STZ-induced diabetic mice with RYGB (n = 6). e. Bioluminescence imaging (BLI) in STZ-induced diabetic MIP-luc mice. BLI was performed in MIP-luc mice one day before RYGB and at 1, 2 and 4 weeks after surgery. Luciferase is expressed as the regions of interest (ROI). STZ-Control, untreated STZ-induced diabetic mice (n = 6); and STZ-RYGB, STZ-induced diabetic mice with RYGB (n = 4).
db/db mice (12 weeks of age) is reduced to 25% of that in young prediabetic BKS-db/db mice (6 weeks of age). At the meantime, plasma adiponectin is also reduced to 50%. Adiponectin has been shown to induce ERK and Akt phosphorylation, stimulate insulin secretion and protect β-cells against apoptosis [40]. Gastric bypass preserves adiponectin expression, contributing to the prevention of β-cell exhaustion, and maintains normal insulinemia and normoglycemia when RYGB is performed in prediabetic BKS-db/db mice.

Both B6-db/db and BKS-db/db mice reveal increased blood glucose; however, B6-db/db mice glucose levels peak then decrease with aging due to β-cell hypertrophy and do not develop the full phenotype of T2D [15]. Gastric bypass improved glucose tolerance throughout the 12-week period in B6-db/db mice. T2D is characterized by a combination of genetic and epigenetic factors, and it is increasingly attributed to environmental factors. NONcNZO10/LtJ (NZO) is a new polygenic strain developed to more realistically model human obesity induced T2D. Consistent with previous reports [25,26], our results show that NZO male mice develop hyperglycemia and exhibited moderate to severe liver steatosis and islet atrophy in 40% of mice. HFD (60% fat)-feeding results in hyperglycemia in 100% of NZO male mice. Insulin+ cells are reduced in HFD-induced diabetic NZO mice due to β-cell apoptosis, as we found in the BKS-db/db model. RYGB preserves β-cell mass, maintains normoglycemia and prevents HFD-induced diabetes, suggesting that genetic- and HFD-mediated diabetes can be prevented by gastric bypass.

STZ targets insulin-producing β-cells in the pancreas and results in severe damage of β-cells in mice, mimicking T1D phenotypes. Recent studies have suggested that gastric bypass yields metabolic benefits as well as leads to better cardiovascular outcomes for the treatment of T1D [41,42]. However, our results show that gastric bypass neither rescues damaged β-cells nor improves hyperglycemia in STZ-induced diabetic mice. We understand that one major limitation of our findings relates to the different proliferation of β-cells, i.e. many mitogens, growth factors and nutrients have been shown to induce expansion in rodent models. However, human β-cells show poor responsiveness to these stimuli [43]. The definition of prediabetes in the clinic is that blood glucose level (100 to 125 mg/dL) is higher than it should be (in normal condition) but not high enough to diagnose diabetes (≥ 126 mg/dL) [44]. Consequently, the gastric bypass related results in mice must be carefully interpreted concerning human implications.

In conclusion, gastric bypass results in sustained normoglycemia and improved glucose tolerance associated with preservation of β-cells in prediabetic BKS-db/db mice. These effects are independent of weight loss. Gastric bypass also prevents the development of overt diabetes in HFD-fed NZO mice. In adult diabetic BKS-db/db mice, however, gastric bypass neither reverses diabetes nor improves β-cell viability. Similarly, gastric bypass did not reverse STZ-induced overt diabetes. Our findings suggest that RYGB improves hyperglycemia and must be performed before β-cells are severely damaged.

Supporting information
S1 File.
(DOCX)

Author Contributions
Formal analysis: Deng Ping Yin.
Investigation: Chenyu Zhu, Rui Xu, Yuxin Li, Michael Andrade, Deng Ping Yin.
Methodology: Deng Ping Yin.
Supervision: Deng Ping Yin.
Validation: Deng Ping Yin.
Visualization: Deng Ping Yin.
Writing – original draft: Deng Ping Yin.
Writing – review & editing: Michael Andrade, Deng Ping Yin.

References
1. Razani B, Semenkovich CF: Getting away from glucose: stop sugarcoating diabetes. Nat Med 2009, 15(4):372–373. https://doi.org/10.1038/nm0409-372 PMID: 19350008
2. Cerf ME: Beta Cell Physiological Dynamics and Dysfunctional Transitions in Response to Islet Inflammation in Obesity and Diabetes. Metabolites 2020, 10(11). https://doi.org/10.3390/metabo10110452 PMID: 33182622
3. Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ: Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes 2008, 57(11):3007–3012. https://doi.org/10.2337/db08-0445 PMID: 18678615
4. Baron AD: Impaired glucose tolerance as a disease. Am J Cardiol 2001, 88(6A):16H–19H. https://doi.org/10.1016/s0002-9149(01)01832-x PMID: 11576521
5. Fonseca VA: Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009, 32 Suppl 2:S151–156. https://doi.org/10.2337/dc09-S301 PMID: 19875543
6. Wagner R, Heni M, Tabak AG, Machann J, Schick F, Randrianarisoa E, et al: Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nature medicine 2021. https://doi.org/10.1038/s41591-020-1116-9 PMID: 33398163
7. Bergman RN, Finegood DT, Kahn SE: The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002, 32 Suppl 3:35–45. https://doi.org/10.1046/j.1365-2362.32.s3.5. x PMID: 12028373
8. Butler AE, Janson J, Soeller WC, Butler PC: Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52(9):2304–2314. https://doi.org/10.2337/diabetes.52.9. 2304 PMID: 12941770
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102–110. https://doi.org/10.2337/diabetes.52.1.102 PMID: 12502499
10. Pournaras DJ, Aasheim ET, Sovik TT, Andrews R, Mahon D, Welbourn R, et al: Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. The British journal of surgery 2012, 99(1):100–103. https://doi.org/10.1002/bjs.7704 PMID: 22021090
11. Reoch J, Mottillo S, Shimony A, Filion KB, Christou NV, Joseph L, et al: Safety of laparoscopic vs open bariatric surgery: a systematic review and meta-analysis. Arch Surg 2011, 146(11):1314–1322. https://doi.org/10.1001/archsurg.2011.270 PMID: 22106325
12. Van Nieuenhove Y, Dambrauskas Z, Campillo-Soto A, van Dielen F, Wiewer R, Janssen I, et al: Pre-operative very low-calorie diet and operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch Surg 2011, 146(11):1300–1305. https://doi.org/10.1001/archsurg.2011.273 PMID: 22106323
13. Stevens JW, Khunti K, Harvey R, Johnson M, Preston L, Woods HB, et al: Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes research and clinical practice 2015, 107 (3):320–331. https://doi.org/10.1016/j.diabres.2015.01.027 PMID: 25638454
14. Kahn SE, Cooper ME, Del Prato S: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014, 383(9922):1068–1083. https://doi.org/10.1016/S0140-6736 (13)62154-6 PMID: 24315620
15. Lutz TA: An Overview of Rodent Models of Obesity and Type 2 Diabetes. Methods in molecular biology 2020, 2128:11–24. https://doi.org/10.1007/978-1-0716-0385-7_2 PMID: 32180183
16. Yin DP, Gao Q, Ma LL, Yan W, Williams PE, McGuinness OP, et al: Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. *Annals of surgery* 2011, 254(1):73–82. https://doi.org/10.1097/SLA.0b013e3182197035 PMID: 21522012
17. Xu R, Zhu C, Pierre JF, Yin DP: Gastric Bypass Improves Obesity and Glucose Tolerance Independent of Gastric Pouch Size. *Obesity surgery* 2020, 30(5):1635–1641. https://doi.org/10.1007/s11695-020-04403-9 PMID: 31927685
18. Dantas WS, Roschel H, Murai IH, Gil S, Davuluri G, Axelrod CL, et al: Exercise-Induced Increases in Insulin Sensitivity After Bariatric Surgery Are Mediated By Muscle Extracellular Matrix Remodeling. *Diabetes* 2020, 69(8):1675–1691. https://doi.org/10.2337/db19-1180 PMID: 32409493
19. Stevenson M, Lee J, Lau RG, Brathwaite CEM, Ragolia L: Surgical Mouse Models of Vertical Sleeve Gastrectomy and Roux-en Y Gastric Bypass: a Review. *Obesity surgery* 2019, 29(12):4084–4094. https://doi.org/10.1007/s11695-019-04205-8 PMID: 31630327
20. Peyot ML, Pepin E, Lamontagne J, Latour MG, Zarrouki B, Lussier R, et al: Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass. *Diabetes* 2010, 59(9):2178–2187. https://doi.org/10.2337/db09-1452 PMID: 20547980
21. Inada S, Kaneko S, Suzuki K, Miyazaki J, Asakura H, Fujiwara M: Rectification of diabetic state in C57BL/6J-db/db mice by the implantation of pancreatic beta cell line MIN6. *Diabetes research and clinical practice* 1996, 32(3):125–133. https://doi.org/10.1016/0168-8227(96)01249-1 PMID: 8658200
22. Leiter EH, Prochazka M, Shultz LD: Effect of immunodeficiency on diabetogenesis in genetically diabetic (db/db) mice. *Journal of immunology* 1987, 138(10):3224–3229. PMID: 3553324
23. Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during progression to diabetes. *Diabetes* 2004, 53 Suppl 3:S16–21. https://doi.org/10.2337/diabetes.53.suppl_3.s16 PMID: 15561905
24. Han MS, Chung KW, Cheon HG, Rhee SD, Yoon CH, Lee MK, et al: Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. *Diabetes* 2009, 58(2):329–336. https://doi.org/10.2337/db08-0080 PMID: 19171749
25. Knebel B, Goddeke S, Hartwig S, Horbelt T, Fahlbusch P, Al-Hasani H, et al: Alteration of Liver Peroxisomal and Mitochondrial Functionality in the NZO Mouse Model of Metabolic Syndrome. *Proteomics Clin Appl* 2012, 12(1). https://doi.org/10.1002/prca.201700028 PMID: 29068532
26. Kluge R, Schemneck S, Schurmann A, Joost HG: Pathophysiology and genetics of obesity and diabetes in the New Zealand obese mouse: a model of the human metabolic syndrome. *Methods in molecular biology* 2012, 933:59–73. https://doi.org/10.1007/978-1-62703-068-7_5 PMID: 22893401
27. McEvoy RC, Andersson J, Sandler S, Hellerstrom C: Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. *The Journal of clinical investigation* 1984, 74(3):715–722. https://doi.org/10.1172/JCI111487 PMID: 6088584
28. Yin D, Tao J, Lee DD, Shen J, Hara M, Lopez J, Kuznetsov A, et al: Recovery of islet beta-cell function in streptozotocin-induced diabetic mice: an indirect role for the spleen. *Diabetes* 2006, 55(12):3256–3263. https://doi.org/10.2337/db05-1275 PMID: 17130466
29. Park SY, Wang X, Chen Z, Powers AC, Magnuson MA, Head WS, et al: Optical imaging of pancreatic beta cells in living mice expressing a mouse insulin I promoter–firefly luciferase transgene. *Genesis* 2005, 43(2):80–86. https://doi.org/10.1002/gene.20157 PMID: 16108006
30. Yin DP, Boyd KL, Williams PE, Abumrad NN, Wasserman DH: Mouse Models of Bariatric Surgery. *Curr Protoc Mouse Biol* 2012, 2(4):295–306. https://doi.org/10.1002/9780470942390.mo120087 PMID: 26069016
31. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Piroetto J: Evaluating the glucose tolerance test in mice. *American journal of physiology Endocrinology and metabolism* 2008, 295(6):E1323–1332. https://doi.org/10.1152/ajpendo.90617.2008 PMID: 18812462
32. Yin D, Ding JW, Shen J, Ma L, Hara M, Chong AS: Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2006, 6(1):60–68. https://doi.org/10.1111/j.1600-6143.2005.01157.x PMID: 16433757
33. Gao Q, Ma LL, Gao X, Yan W, Williams P, Yin DP: TLR4 mediates early graft failure after intraportal islet transplantation. *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2010, 10(7):1588–1596. https://doi.org/10.1111/j.1600-6143.2010.03151.x PMID: 20642688
34. Coleman DL: The influence of genetic background on the expression of mutations at the diabetes (db) locus in the mouse. VI: Hepatic malic enzyme activity is associated with diabetes severity. *Metabolism: clinical and experimental* 1992, 41(10):1134–1136.
35. Leiter EH, Chapman HD, Coleman DL: The influence of genetic background on the expression of mutations at the diabetes locus in the mouse. V. Interaction between the db gene and hepatic sex steroid sulfotransferases correlates with gender-dependent susceptibility to hyperglycemia. *Endocrinology* 1989, 124(2):912–922. https://doi.org/10.1210/endo-124-2-912 PMID: 2912706

36. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006, 444(7121):840–846. https://doi.org/10.1038/nature05482 PMID: 17167471

37. Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA, et al: Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. *American journal of physiology Gastrointestinal and liver physiology* 2011, 300(5):G795–802. https://doi.org/10.1152/ajpgi.00019.2011 PMID: 21372167

38. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, et al: Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. *Diabetes* 2006, 55(7):2025–2031. https://doi.org/10.2337/db06-0068 PMID: 16804072

39. Kodama H, Fujita M, Yamauchi I: Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. *Diabetologia* 1994, 37(8):739–744. https://doi.org/10.1007/BF00404329 PMID: 7988774

40. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB: Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. *The Journal of biological chemistry* 2010, 285(44):33623–33631. https://doi.org/10.1074/jbc.M109.085084 PMID: 20709750

41. Hoskuldsdottir G, Ekelund J, Miftaraj M, Wallenius V, Ottosson J, Naslund I, et al: Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. *Diabetes care* 2020, 43(12):3079–3085. https://doi.org/10.2337/dc20-0388 PMID: 33023988

42. Vilarrasa N, Rubio MA, Minambres I, Flores L, Caixas A, Ciudin A, et al: Long-Term Outcomes in Patients with Morbid Obesity and Type 1 Diabetes Undergoing Bariatric Surgery. *Obesity surgery* 2017, 27(4):856–863. https://doi.org/10.1007/s11695-016-2390-y PMID: 27709487

43. Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF: Human beta-cell proliferation and intracellular signaling: driving in the dark without a road map. *Diabetes* 2012, 61(9):2205–2213. https://doi.org/10.2337/db12-0018 PMID: 22751699

44. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. *Diabetes care* 2019, 42(Suppl 1):S13–S28. https://doi.org/10.2337/dc19-S002 PMID: 30559228